Abstract
BackgroundPrevious real-world studies of first-line (1L) atezolizumab+carboplatin+etoposide for ES-SCLC in the US community oncology setting showed similar treatment durations (medians: 4.9;5.7 months) as in the IMpower133 trial (median: 4.7 months)...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
